Larimar Therapeutics (LRMR) Current Assets (2013 - 2025)

Larimar Therapeutics' Current Assets history runs 13 years deep, the most recent figure standing at $142.0 million for Q4 2025.

• Quarterly Current Assets fell 27.28% year-over-year to $142.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $142.0 million (down 27.28% YoY) and the FY2025 annual result came in at $142.0 million, down 27.28% from the prior year.
• Current Assets was $142.0 million for Q4 2025 at Larimar Therapeutics, down from $183.2 million in the prior quarter.
• Across five years, Current Assets topped out at $231.1 million in Q2 2024 and bottomed at $56.7 million in Q2 2022.
• A 5-year average of $129.9 million and a median of $117.1 million in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2021 — Current Assets plunged 37.84% — and 2024, when it soared 117.07%.
• Larimar Therapeutics' Current Assets stood at $72.2 million in 2021, then surged by 67.22% to $120.7 million in 2022, then slipped by 25.31% to $90.2 million in 2023, then surged by 116.58% to $195.3 million in 2024, then slipped by 27.28% to $142.0 million in 2025.
• Business Quant data shows LRMR's Current Assets at $142.0 million in Q4 2025, $183.2 million in Q3 2025, and $145.6 million in Q2 2025.